跳至主要内容
临床试验/NCT03300661
NCT03300661已完成不适用

Open-label, Non-Pharmacological, Intervention Cohort Study Without Control Arm, in Patients With Non Alcoholic Fatty Liver Disease and in Healthy Subjects.

Università degli Studi di Brescia2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2017年6月13日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
100
试验地点
2
主要终点
Weight loss

研究概览

简要总结

The study is an open-label intervention non pharmacological Cohort Study without control arm in patients with Non Alcoholic Fatty Liver Disease (NAFLD) and in healthy subjects.

The intervention in patients with NAFLD is educational, providing personalized suggestions to improve diet and physical activity; the intervention in healthy subjects is educational, providing general suggestions to improve diet and physical activity.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 59 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Presence of Fatty Liver at ultrasonography

排除标准

  • Pregnancy;
  • Breast Feeding
  • Cirrhosis or End Stage Liver Disease
  • Fatty Liver due to Hepatic Diseases other than Non Alcoholic Fatty Liver disease
  • Concomitant severe clinical condition

研究组 & 干预措施

Mediterranean Style

Experimental

Educational intervention with personalized suggestions to improve diet and physical activity

干预措施: Mediterranean Style (Behavioral)

结局指标

主要结局

Weight loss

时间窗: 12 months

A reduction of at least 3 Kg

Body Mass Index (BMI) decrease

时间窗: 12 months

A dicresae of at least 1Kg/m2

Waist Circumference (WC) decrease

时间窗: 12 months

A decrease of at least 1.5 cm

次要结局

  • Blood cholesterol level decrease(12 months)
  • Blood triglycerides level dicrease(12 months)
  • Blood sugar level decrease(12 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Chiara Ricci

Associate Professor

Università degli Studi di Brescia

研究点 (2)

Loading locations...

相似试验

进行中(未招募)
1 期
Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety inPatients with Asthma (Long-Term Follow-Up)MedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthma
EUCTR2017-002134-23-Outside-EU/EEASanofi-aventis groupe
进行中(未招募)
1 期
Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients with Asthma (Long-Term Follow-Up)Asthma
EUCTR2017-002134-23-BEsanofi-aventis groupe750
进行中(未招募)
1 期
Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients with Asthma (Long-Term Follow-Up)MedDRA version: 20.0 Level: PT Classification code 10003553 Term: Asthma System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthma
EUCTR2017-002134-23-FRsanofi-aventis groupe750
进行中(未招募)
1 期
Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients with Asthma (TRAVERSE CONTINUATION)MedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthma
EUCTR2017-002134-23-NLsanofi-aventis groupe750
进行中(未招募)
1 期
Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients with Asthma (Long-Term Follow-Up)MedDRA version: 20.0Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthma
EUCTR2017-002134-23-DEsanofi-aventis groupe750
Non Alcoholic Fatty Liver Disease: Nutritional... | 临床试验